(51) International Patent Classification 3:
C12N 15/00, 1/00; C12P 21/00, 21/02, 21/04

(11) International Publication Number: WO 81/00114

(43) International Publication Date: 22 January 1981 (22.01.81)

(21) International Application Number: PCT/US80/00838

(22) International Filing Date: 3 July 1980 (03.07.80)

(31) Priority Application Number: 055,126

(32) Priority Date: 5 July 1979 (05.07.79)

(33) Priority Country: US


(72) Inventors: GOEDDEL, David, V.; 1449 Benito Street, Burlingame, CA 94010 (US); HEYNKER, Herbert, L.; 2621 Easton Drive, Burlingame, CA 94010 (US).

(74) Agents: Berman, Charles et al.; Lyon & Lyon, 800 Wilshire Boulevard, Los Angeles, CA 90017 (US).

(81) Designated States: BR, DK, NO, RO, SU.

Published
With international search report
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: MICROBIAL EXPRESSION OF QUASI-SYNTHETIC GENES

(57) Abstract

Methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
</tr>
<tr>
<td>DE</td>
<td>Germany, Federal Republic of</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
</tr>
<tr>
<td>GB</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
</tr>
<tr>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>SU</td>
<td>Soviet Union</td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
</tr>
</tbody>
</table>
DESCRIPTION

MICROBIAL EXPRESSION OF QUASI-SYNTHETIC GENES

Background of the Invention

Genetic Expression

The DNA (deoxyribonucleic acid) of which genes are made comprises both protein-encoding or "structural" genes and control regions that mediate the expression of their information through provision of sites for RNA polymerase binding, information for ribosomal binding sites, etc. Encoded protein is "expressed" from its corresponding DNA by a multistep process within an organism by which:

1. The enzyme RNA polymerase is activated in the control region (hereafter the "promoter") and travels along the structural gene, transcribing its encoded information into messenger ribonucleic acid (mRNA) until transcription is ended at one or more "stop" codons.

2. The mRNA message is translated at the ribosomes into a protein for whose amino acid sequence the gene encodes, beginning at a translation "start" signal, most commonly ATG (which is translated "f-methionine").

In accordance with the genetic code, DNA specifies each amino acid by a triplet or "codon" of three adjacent nucleotides individually chosen from adenosine, thymidine, cytidine and guanine or, as used herein, A, T, C, or G. These appear in the coding strand or coding sequence of double-stranded ("duplex") DNA, whose remaining or "complementary" strand is formed of nucleotides ("bases") which hydrogen bond to their complements in the coding strand. A complements T, and C complements G. These and other subjects relating to the background of the
invention are discussed at length in Benjamin Lewin, *Gene Expression* 1, 2 (1974) and 3 (1977), John Wiley and Sons, N.Y. This and the other publications alluded to herein are incorporated by reference.

5 **DNA Cleavage and Ligation**

A variety of techniques are available for DNA recombination, according to which adjoining ends of separate DNA fragments are tailored in one way or another to facilitate ligation. The latter term refers to the formation of phosphodiester bonds between adjoining nucleotides, most often through the agency of the enzyme T4 DNA ligase. Thus, blunt ends may be directly ligated. Alternatively, fragments containing complementary single strands at their adjoining ends are advantaged by hydrogen bonding which positions the respective ends for subsequent ligation. Such single strands, referred to as cohesive termini, may be formed by the addition of nucleotides to blunt ends using terminal transferase, and sometimes simply by chewing back one strand of a blunt end with an enzyme such as λ-exonuclease. Again, and most commonly, resort may be had to restriction endonucleases (hereafter, "restriction enzymes"), which cleave phosphodiester bonds in and around unique sequences of nucleotides of about 4-6 base pairs in length ("restriction sites"). Many restriction enzymes and their recognition sites are known. See, e.g., R. J. Roberts, *CRC Critical Reviews in Biochemistry*, 123 (Nov. 1976). Many make staggered cuts that generate short complementary single-stranded sequences at the ends of the duplex fragments. As complementary sequences, the protruding or "cohesive" ends can recombine by base pairing. When two different molecules are cleaved with this enzyme, crosswise pairing of the complementary single strands generates a new DNA molecule, which can be given covalent integrity by using ligase to seal the single strand breaks that remain at
the point of annealing. Restriction enzymes which leave
coterminal or "blunt" ends on duplex DNA that has been
cleaved permit recombination via, e.g., T4 ligase with
other blunt-ended sequences.

5 Cloning Vehicles and Recombinant DNA

For present purposes, a "cloning vehicle" is a
nonchromosomal length of duplex DNA comprising an intact
replicon such that the vehicle can be replicated when
placed within a unicellular organism ("microbe") by
transformation. An organism so transformed is called a
"transformant". Presently, the cloning vehicles commonly
in use are derived from viruses and bacteria and most
commonly are loops of bacteria DNA called "plasmids".

Advances in biochemistry in recent years have led
to the construction of "recombinant" cloning vehicles in
which, for example, plasmids are made to contain exo-
genous DNA. In particular instances the recombinant may
include "heterologous" DNA, by which is meant DNA that
codes for polypeptides ordinarily not produced by the
organism susceptible to transformation by the recombinant
vehicle. Thus, plasmids are cleaved with restriction
enzymes to provide linear DNA having ligatable termini.
These are bound to an exogenous gene having ligatable
termi to provide a biologically functional moiety
with an intact replicon and a phenotypical property
useful in selecting transformants. The recombinant
moiety is inserted into a microorganism by transformation
and the transformant is isolated and cloned, with the
object of obtaining large populations that include
copies of the exogenous gene and, in particular cases,
with the further object of expressing the protein for
which the gene codes. The associated technology and its
potential applications are reviewed in extenso in the
Miles International Symposium Series 10: Recombinant
Molecules: Impact on Science and Society, Beers and
Recombinant DNA Expression

Aside from the use of cloning vehicles to increase the supply of genes by replication, there have been attempts, some successful, to actually express proteins for which the genes code. In the first such instance a gene for the brain hormone somatostatin under the influence of the lac promoter was expressed in E. Coli bacteria. K. Itakura et al, Science 198, 1056 (1977). More recently, the A and B chains of human insulin were expressed in the same fashion and combined to form the hormone. D. V. Goeddel et al., Proc. Nat'l. Acad. Sci., USA 76, 106 (1979). In each case the genes were constructed in their entirety by synthesis. In each case, proteolytic enzymes within the cell would apparently degrade the desired product, necessitating its production in conjugated form, i.e., in tandem with another protein which protected it by compartmentalization and which could be extracellularly cleaved away to yield the product intended. This work is described in the following published British patent specifications of the assignee of the present application: GB 2007 675 A; GB 2 007 670 A; GB 2 007 676 A; and GB 2 008 123 A.

While the synthetic gene approach has proven useful in the several cases thus far discussed, real difficulties arise in the case of far larger protein products, e.g., growth hormone, interferon, etc., whose genes are correspondingly more complex and less susceptible to facile synthesis. At the same time, it would be desirable to express such products unaccompanied by conjugate protein, the necessity of whose expression requires diversion of resources within the organism better committed to construction of the intended product.

Other workers have attempted to express genes derived not by organic synthesis but rather by reverse transcription from the corresponding messenger RNA purified from tissue. Two problems have attended this approach. To begin with, reverse transcriptase may stop
transcription from mRNA short of completing cDNA for the entire amino acid sequence desired. Thus, for example, Villa-Komaroff et al obtained cDNA for rat proinsulin which lacked codons for the first three amino acids of the insulin precursor. Proc. Nat'l. Acad. Sci., USA 75 3727 (1978). Again, reverse transcription of mRNA for polypeptides that are expressed in precursor form has yielded cDNA for the precursor form rather than the bioactive protein that results when, in a eukaryotic cell, leader sequences are enzymatically removed. Thus far, no bacterial cell has been shown to share that capability, so that mRNA transcripts have yielded expression products containing the leader sequences of the precursor form rather than the bioactive protein itself. Villa-Komaroff, supra (rat proinsulin); P. H. Seeburg et al, Nature 276, 795 (1978) (rat pregrowth hormone).

Finally, past attempts by others to bacterially express human hormones (or their precursors) from mRNA transcripts have on occasion led only to the production of conjugated proteins not apparently amenable to extra-cellular cleavage, e.g., Villa-Komaroff, supra, (penicillinase-proinsulin); Seeburg, supra (beta-lactamase-pregrowth hormone).

**Human Growth Hormone**

Human growth hormone ("HGH") is secreted in the human pituitary. It consists of 191 amino acids and, with its molecular weight of about 21,500, is more than three times as large as insulin. Until the present invention, human growth hormone could be obtained only by laborious extraction from a limited source -- the pituitary glands of human cadavers. The consequent scarcity of the substance has limited its applications to the treatment of hypopituitary dwarfism, and even here reliable estimates suggest that human-derived HGH is available in sufficient quantity to serve not
more than about 50% of afflicted subjects.

In summary, a need has existed for new methods of producing HGH and other polypeptide products in quantity, and that need has been particularly acute in the case of polypeptides too large to admit of organic synthesis or, for that matter, microbial expression from entirely synthetic genes. Expression of mammalian hormones from mRNA transcripts has offered the promise of sidestepping difficulties that attend the synthetic approach, but until the present has permitted only microbial production of bio-inactive conjugates from which the desired hormone could not practicably be cleaved.

Summary of the Invention

The present invention provides methods and means for expressing quasi-synthetic genes wherein reverse transcription provides a substantial portion, preferably a majority, of the coding sequence without laborious resort to entirely synthetic construction, while synthesis of the remainder of the coding sequence affords a completed gene capable of expressing the desired polypeptide unaccompanied by bio-inactivating leader sequences or other extraneous protein. Alternatively, the synthetic remainder may yield a proteolysis-resistant conjugate so engineered as to permit extra-cellular cleavage of extraneous protein, yielding the bioactive form. The invention accordingly makes available methods and means for microbial production of numerous materials hitherto produced only in limited quantity by costly extraction from tissue, and still others previously incapable of industrial manufacture. In its most preferred embodiment the invention represents the first occasion in which a medically significant polypeptide hormone (human growth hormone) has been bacterially expressed while avoiding both intracellular proteolysis and the necessity of compartmentalizing the bioactive form in extraneous protein pending extracellular cleavage.
Microbial sources for human growth hormone made available by the invention offer, for the first time, ample supplies of the hormone for treatment of hypopituitaric dwarfism, together with other applications heretofore beyond the capacity of tissue-derived hormone sources, including diffuse gastric bleeding, pseudarthrosis, burn therapy, wound healing, dystrophy and bone knitting.

The manner in which these and other objects and advantages of the invention may be obtained will appear more fully from the detailed description which follows, and from the accompanying drawings relating to a preferred embodiment of the invention, in which:

Figure 1 depicts the synthetic scheme for construction of a gene fragment coding for the first 24 amino acids of human growth hormone, together with the start signal ATG and linkers used in cloning. The arrows in the coding or upper strand ("U") and in the complementary or lower strand ("L") indicate the oligonucleotides joined to form the depicted fragment;

Figure 2 depicts joinder of the "U" and "L" oligonucleotides to form the gene fragment of Figure 1, and its insertion in a plasmid cloning vehicle;

Figure 3 illustrates the DNA sequence (coding strand only) of the Hae III restriction enzyme fragment of a pituitary mRNA transcript, with the numbered amino acids of human growth hormone for which they code. Key restriction sites are indicated, as is DNA (following "stop") for untranslated mRNA;

Figure 4 illustrates the construction of a cloning vehicle for a gene fragment coding for the amino acids of human growth hormone not synthetically derived, and the construction of that gene fragment as complementary DNA by reverse transcription from mRNA isolated from a human pituitary source; and

Figure 5 illustrates the construction of a plasmid capable, in bacteria, of expressing human growth hormone, beginning with the plasmids of Figures 2 and 3.
Detailed Description of the Invention

The general approach of the invention involves the combination in a single cloning vehicle of plural gene fragments which in combination code for expression of the desired product. Of these, at least one is a cDNA fragment derived by reverse transcription from mRNA isolated from tissue, as by the method of A. Ullrich et al., *Science* 196, 1313 (1977). The cDNA provides a substantial portion, and preferably at least a majority, of the codons for the desired product, while remaining portions of the gene are supplied synthetically. The synthetic and mRNA transcript fragments are cloned separately to provide ample quantities for use in the later combination step.

A variety of considerations influence distribution of codons for the end product as between synthetic and cDNA, most particularly the DNA sequence of complementary DNA determined as by the method of Maxam and Gilbert, *Proc. Nat'l Acad. Sci. USA* 74, 560 (1977). Complementary DNA obtained by reverse transcription will invariably contain codons for at least a carboxy terminal portion of the desired product, as well as other codons for untranslated mRNA downstream from the translation stop signal(s) adjacent the carboxy terminus. The presence of DNA for untranslated RNA is largely irrelevant, although unduly lengthy sequences of that kind may be removed, as by restriction enzyme cleavage, to conserve cellular resources employed in replicating and expressing the DNA for the intended product. In particular cases, the cDNA will contain codons for the entire amino acid sequence desired, as well as extraneous codons upstream from the amino terminus of the intended product. For example, many if not all polypeptide hormones are expressed in precursor form with leader or signal sequences of protein involved, e.g., in transport to the cellular membrane. In expression from eukaryotic cells, these sequences are enzymatically removed, such that the
hormone enters the periplasmic space in its free, bioactive form. However, microbial cells cannot be relied upon to perform that function, and it is accordingly desirable to remove sequences coding for such signals or leader sequences from the mRNA transcript. In the course of that removal process the translation start signal is also lost, and almost invariably some codons for the intended product will be removed as well. The synthetic component of the quasi-synthetic gene product of the invention returns these latter codons, as well as supplying anew a translation start signal where the vehicle into which the hybrid gene will ultimately be deployed itself lacks a properly positioned start.

Elimination of the leader sequence from pregrowth hormone cDNA is advantaged by the availability of a restriction site within the growth hormone-encoding portion of the gene. The invention may nevertheless be practiced without regard to the availability of such a site, or in any event without regard to the availability of a restriction site sufficiently near the amino terminus of the desired polypeptide as to obviate the need for extensive synthesis of the gene component not derived from mRNA. Thus, in any cDNA coding for the desired polypeptide and a leader or other bioinactivating sequence the boundary between the latter's codons and those of the mature polypeptide will appear from the amino acid sequence of the mature polypeptide. One may simply digest into the gene coding from the peptide of choice, removing the unwanted leader or other sequence.

Thus, for example, given cDNA such as:

```
5'         a---b             TTAAGCCCTGATCGT ... etc.
            |                 
            c---d
3'         AATTCGGGACTAGCA ...
```
where the endpoint of digestion is indicated by arrow, reaction conditions for exonuclease digestion may be chosen to remove the upper sequences "a" and "b", whereafter S1 nuclease digestion will automatically eliminate the lower sequences "c" and "d". Alternatively and more precisely, one may employ DNA polymerase digestion in the presence of deoxynucleotide triphosphates ("d(A,T,C,G)TP"). Thus, in the foregoing example, DNA polymerase in the presence of dGTP will remove sequence "c" (then stop at "G"), S1 nuclease will then digest "a"; DNA polymerase in the presence of dTTP will remove "d", (then stop at "T") and S1 nuclease will then excise "b", and so on. See generally A. Kornberg, DNA Synthesis, pp. 87-88, W. H. Freeman and Co., San Francisco (1974).

More preferably, one may simply construct a restriction site at a convenient point within the portion of the cDNA coding for the desired product, by an application of the mismatch repair synthesis technique of A. Razin et al, Proc. Nat'1 Acad. Sci. USA 75, 4268 (1978). By this technique one or more bases may be substituted in an existing DNA sequence, using primers containing the mismatched substituent. At least seven palindromic 4-base pair sequences are uniquely recognized by known restriction enzymes, i.e., AGCT (Alu I), CCGG (Hpa II), CGCG (Tha I), GATC (Sau 3A), GCGC (Hha), GGCC (Hae III), and TCGA (Taq I). Where the cDNA sequence contains a sequence differing from one such site in a single base, as statistically is highly likely, repair synthesis will yield replicate cDNA containing the proper, substituent base and hence the desired restriction site. Cleavage will delete DNA for the unwanted leader, after which synthesis will replace codons required for expression of the complete polypeptide. E.g.,:
It will be appreciated, of course, that longer restriction sites may be likewise inserted where desired, or that successive repairs may create 4-base pair restriction sites where only two bases common to the site appear at the desired point, etc.

Applications will appear in which it is desirable to express not only the amino acid sequence of the intended product, but also a measure of extraneous but specifically engineered protein. Four such applications may be mentioned by way of example. First, the quasi-synthetic gene may represent a hapten or other immunological determinant upon which immunogenicity is conferred by conjugation to additional protein, such that vaccines are produced. See generally, G.B. patent specification 2 008 123A. Again, it may be desirable for biosafety reasons to express the intended product as a conjugate other, bio-inactivating protein, so designed as to permit extracellular cleavage to yield the active form. Third, applications will be presented in which transport signal polypeptides will precede the desired product, to permit production of the same by excretion through the cell membrane, so long as the signal peptide can then be cleaved. Finally, extraneous conjugate
designed to permit specific cleavage extracellularly may be employed to compartmentalize intended products otherwise susceptible to degradation by proteases endogenous to the microbial host. At least in the latter three applications, the synthetic adaptor molecular employed to complete the coding sequence of the mRNA transcript can additionally incorporate codons for amino acid sequences specifically cleavable, as by enzymatic action. For example, trypsin or chymotrypsin will cleave specifically at arg-arg or lys-lys, etc. See GB 2 008 123A, supra.

From the foregoing, it will be seen that in its broadest aspect the invention admits of manifold applications, each having in common these attributes:

-- a mRNA transcript is employed which codes for a substantial portion of the intended polypeptide's amino acid sequence but which, if expressed alone, would produce a different polypeptide either smaller or larger than the intended product;

-- protein-encoding codons for amino acid sequences other than those contained in the intended product, if any, are removed;

-- organic synthesis yields fragment(s) coding for the remainder of the desired sequence; and

-- the mRNA transcript and synthetic fragment(s) are combined and disposed in a promoter-containing cloning vehicle for replication and expression of either the intended product absent extraneous conjugated protein, or intended product conjugated to but specifically cleavable from extraneous protein.

Of course, the expression product will in every case commence with the amino acid coded for by the translation start signal (in the case of ATG, f-methionine). One can expect this to be removed intracellularly, or in any
event to leave the bioactivity of the ultimate product essentially unaffected.

Although it provides a method of general applicability in the production of useful proteins, including antibodies, enzymes and the like, the invention is particularly suited to the expression of mammalian polypeptide hormones and other substances having medical applications, e.g., glucagon, gastrointestinal inhibitory polypeptide, pancreatic polypeptide, adrenocorticotropic, beta-endorphins, interferon, urokinase, blood clotting factors, human albumin, and so on. A preferred embodiment illustrative of the invention is next discussed, in which a quasi-synthetic gene coding for human growth hormone is constructed, cloned and microbially expressed.

Construction and Expression of a Cloning Vehicle for Human Growth Hormone

1. Cloning the Hae III fragment of the mRNA transcript (Figs. 3 and 4)

Polyadenylated mRNA for human growth hormone (HGH) was prepared from pituitary growth hormone-producing tumors by the procedure of A. Ullrich et al. *Science* 196, 1313 (1977) 1.5 μg of double strand ("ds") cDNA was prepared from 5 μg of this RNA essentially as described by Wickens et al. *J. Biol Chem.* 253 2483 (1978), except that RNA polymerase "Klenow fragment", H. Klenow, *Proc. Nat'l. Aci. USA.* 65, 168 (1970), was substituted for DNA Polymerase I in the second strand synthesis. The restriction pattern of HGH is such that Hae III restriction sites are present in the 3' noncoding region and in the sequence coding for amino acids 23 and 24 of HGH, as shown in Fig. 3. Treatment of ds HGH cDNA with Hae III gives a DNA fragment of 551 base pairs ("bp"") coding for amino acids 24-191 of HGH. Thus, 90 ng of the cDNA was treated with Hae III, electrophoresed on an 8% polyacrylamide gel, and the region at 550 b.p. eluted. Approximately 1 ng of cDNA was obtained.
pBR322 prepared as in F. Bolivar et al., *Gene* 2 (1977) 95-113 was chosen as the cloning vehicle for the cDNA. pBR322 has been fully characterized, J.G. Sutcliffe, *Cold Spring Harbor Symposium* 43, 70 (1978) is a multicopy replicating plasmid which exhibits both ampicillin and tetracycline resistance owing to its inclusion of the corresponding genes ("ApR" and "TcR", respectively, in Fig. 4), and which contains recognition sites for the restriction enzymes Pst I, EcoRI and Hind III as shown in the Figure.

Cleavage products of both Hae III and Pst I are blunt ended. The GC tailing method of Chang, A.C.Y. et al. *Nature* 275 617 (1978) could accordingly be employed to combine the blunt-ended products of Pst I cleavage of pBR322 and of Hae III digestion of the mRNA transcript, inserting the cDNA fragment into the Pst I site of pBR322 in such manner as to restore the Hae III restriction sites (GG↓CC) on the cDNA while restoring the Pst I restriction sites (CTGCA↓G) at each end of the insert.

Thus, terminal deoxynucleotidyl transferase (TdT) was used to add approximately 20 dC residues per 3' terminus as described previously, Chang, A.Y.C., *supra*. 60 ng of Pst I-treated pBR322 was tailed similarly with about 10 dG residues per 3' terminus. Annealing of the dC-tailed ds cDNA with the dG-tailed vector DNA was performed in 130 ul of 10 mM Tris-Cl (pH 7.5), 100 mM NaCl, 0.25 mM EDTA. The mixture was heated to 70°C, allowed to cool slowly to 37°C (12 hours), then to 20°C (6 hours) before being used to transform E. Coli. x1776. DNA sequence analysis of the plasmid pHGH31 cloned in x1776 by the method of Maxam and Gilbert, *Proc. Nat'l Acad. Sci. USA* 74, 560 (1977) resulted in confirmation of the codons for amino acids 24-191 of HGH, as shown in Figure 3.

E. Coli K-12 strain x1776 has the genotype F- tonA53 dapD8 minA1 supE42 Δ40[gal-uvrB] L- minB2 rfb-2 nalA25 oms-2 thyA57* metC65 oms-1 Δ29[bioH-asd]
cycB2 cycA1 hsdR2. x1776 has been certified by the National Institutes of Health as an EK2 host vector system.

x1776 has an obligate requirement for diaminopimelic acid (DAP) and cannot synthesize the mucopolysaccharide colanic acid. It thus undergoes DAP-less death in all environments where DAP is limiting but sufficient nutrients exist to support cellular metabolism and growth. It requires thymine or thymidine and undergoes thymineless death with degradation of DNA when thymine and thymidine are absent from the environment but when sufficient nutrients are present to sustain metabolic activity. x1776 is extremely sensitive to bile and thus is unable to survive and thus is unable to survive passage through the intestinal tract of rats. x1776 is extremely sensitive to detergents, antibiotics, drugs and chemicals. x1776 is unable to carry out either dark or photo repair of UV-induced damage and is thus several orders of magnitude more sensitive to sunlight than wild-type strains of E. Coli. x1776 is resistant to many transducing phages and is conjugation deficient for inheritance of many different types of conjugative plasmids due to the presence of various mutations. x1776 is resistant to nalidixic acid, cycloserine and trimethoprim. These drugs can therefore be added to media to permit monitoring of the strain and to preclude transformation of contaminants during transformation.

x1776 grows with a generation time of about 50 min. in either L broth or Penassay broth when supplemented with 100 μg DAP/ml and 4 μg thymidine/ml and reaches final densities of 8-10 x 10^8 cells/ml at stationary phase. Gentle agitation by swirling and shaking back and forth for a period of 1-2 min. adequately suspends cells with maintenance of 100% viability. Additional details concerning x1776 appear in R. Curtis et al., Molecular Cloning of Recombinant DNA, 99-177, Scott and
2. Construction and Cloning of the Synthetic Gene Fragment (Figs. 1 and 2)

The strategy for construction of the HGH quasi-synthetic gene included construction of a synthetic fragment comprising a blunt-end restriction cleavage site adjacent the point at which the fragment would be joined to the mRNA transcript. Thus, as shown in Fig. 1, the synthetic gene for the first 24 amino acids of HGH contained a Hae III cleavage site following amino acid 23. The distal end of the synthetic fragment was provided with a "linker" that permitted annealing to a single strand terminal resulting from restriction cleavage in the plasmid in which the mRNA transcript and synthetic fragment would ultimately be joined.

As shown in Fig. 1, the 5' ends of the duplex fragment have single stranded cohesive termini for the Eco RI and Hind III restriction endonucleases to facilitate plasmid construction. The methionine codon at the left end provides a site for initiation of translation. Twelve different oligonucleotides, varying in size from undecamer to hexadecamer, were synthesized by the improved phosphotriester method of Crea, R. Proc. Nat'l. Acad. Sci. USA 75, 5765 (1978). These oligonucleotides, U₁ to U₆ and L₁ to L₆, are indicated by arrows.


Three separate T₄ ligase catalyzed reactions were performed: 10 µg of 5'-OH fragment U₁ was combined with the phosphorylated U₂, L₅ and L₆;
phosphorylated U₃, U₄, L₃ and L₄ were combined; and 10 μg of 5'-OH fragment L₁ was combined with the phosphorylated L₂, U₅ and U₆. These ligations were carried out at 4°C for 6 hours in 300 μl of 20 mM Tris-HCl (pH 7.5), 1 mM MgCl₂, 10 mM dithiothreitol, 0.5 mM ATP using 100 units of T₄ ligase. The three ligation mixtures were then combined, 100 units T₄ ligase added, and the reaction allowed to proceed for 12 hours at 20°C. The mixture was ethanol precipitated and electrophoresed on a 10% polyacrylamide gel. The band migrating at 84 base pairs was sliced from the gel and eluted. pBR322 (1 μg) was treated with Eco RI and Hind III, the large fragment isolated by gel electrophoresis and ligated to the synthetic DNA. This mixture was used to transform E. Coli K-12 strain 294 (end A, thi⁻, hsr⁻, hsmK⁺). Strain 294 was deposited October 30, 1978 in the American Type Culture Collection (ATCC No. 31446), without restriction Sequence analysis by the Maxam and Gilbert technique, supra, on the Eco RI - Hind III insert from a plasmid pGH3 of one transformant confirmed that depicted in Figure 1.

3. Construction of Plasmid for the Bacterial Expression of HGH (Fig. 5)

With the synthetic fragment in pGH3 and the mRNA transcript in pGH31, a replicable plasmid containing both fragments was constructed using the expression plasmid pGH6, as shown in Fig. 5. The expression plasmid, which contains tandem lac promoters, was first constructed as follows. A 285 base pair Eco RI fragment containing two 95 base pair UV5 lac promoter fragments separated by a 95 base pair heterologous DNA fragment was isolated from plasmid pKB268, K. Backman, et al., Cell, Vol. 13, 65-71 (1978). The 285 b.p. fragment was inserted into the Eco RI site of pBR322 and a clone pGH1 isolated with the promoters oriented toward and in proper reading phase with the gene for tetracycline
-18-

resistance. The Eco RI site distal to the latter gene was destroyed by partial Eco RI digestion, repair of the resulting single stranded Eco RI ends with DNA polymerase I and recircularization of the plasmid by blunt-end ligation. The resulting plasmid, pGH6, contains a single Eco RI site properly positioned with respect to the promoter system into which the completed gene for HGH could be inserted.

To ready the synthetic fragment for combination with the RNA transcript, 10 μg of pGH3 was cleaved with Eco RI and Hae III restriction endonucleases and the 77 base pair fragment containing coding sequences for HGH amino acids 1-23 was isolated from an 8% polyacrylamide gel.

The plasmid pGH 31 (5μg) was next cleaved with Hae III. The 551 bp HGH sequence and a comigrating 540 bp Hae III fragment of pBR322 were purified by gel electrophoresis. Subsequent treatment with Xma I cleaved only the HGH sequence, removing 39 base pairs from the 3' noncoding region. The resulting 512 bp fragment was separated from the 540 b.p. pBR322 Hae III piece by electrophoresis on a 6% polyacrylamide gel. 0.3 μg of the 77 b.p. Eco RI - Hae III fragment were polymerized with T4 ligase in a 16 μl reaction for 14 hours at 4°C. The mixture was heated to 70°C for 5' to inactivate the ligase, then treated with Eco RI (to cleave fragments which had dimerized through their Eco RI sites) and with Sma I (to cleave Xma I dimers), yielding a 591 b.p. fragment with an Eco RI "cohesive" end and a Sma I "blunt" end. After purification on a 6% polyacrylamide gel, approximately 30 ng of this fragment were obtained. It should be noted that the expression plasmid pGH6 contains no Xma I recognition site. However, Sma I recognizes the same site as Xma I, but cuts through the middle of it, yielding blunt ends. The Sma-cleaved terminus of the fragment derived from gGH 31 can accordingly be blunt end ligated into pGH6.
The expression plasmid pGH6, containing tandem \textit{lac UV5} promoters, was treated successively with \textit{Hind III}, nuclease \textit{S1}, and \textit{Eco RI} and purified by gel electrophoresis. 50 ng of the resulting vector, which had one
\textit{Eco RI} cohesive end and one blunt end was ligated to 10 ng of the 591 bp. HGH DNA. The ligation mixture was used to transform \textit{E. Coli} X1776. Colonies were selected for growth on tetracycline (12.5 \textmu g/ml). It is noteworthy that insertion of the hybrid HGH gene into pGH6 destroys the promoter for the tetracycline resistance gene, but that the tandem \textit{lac} promoter permits read-through of the structural gene for tet resistance, retaining this selection characteristic. Approximately 400 transformants were obtained. Filter hybridization by the Grunstein - Hogness procedure, \textit{Proc. Nat'l. Acad. Sci. USA, 72}, 3961 (1975) identified 12 colonies containing HGH sequences. The plasmids isolated from three of these colonies gave the expected restriction patterns when cleaved with \textit{Hae III}, \textit{Pvu II}, and \textit{Pst I}. The DNA sequence of one clone, pHGH107, was determined.

Human growth hormone expressed by the transformants was easily detected by direct radioimmunoassay performed on serial dilutions of lysed cell supernatants using the Phadebas HGH PRIST kit (Farmacia).

To demonstrate that HGH expression is under the control of the \textit{lac} promoter, pGHG 107 was transformed into \textit{E. Coli} strain D1210 a \textit{lac+ (iQ0+zty+)} , a \textit{lac} repressor overproducer. Meaningful levels of HGH expression could not be detected until addition of the inducer IPTG (isopropylthiogalactoside).

Removal of the \textit{Eco RI} site in pGH107 would leave the ATG start signal the same distance from the ribosome binding site codons of the \textit{lac} promoter as occurs in nature between those codons and the start signal for \textit{B-galactosidase}. To determine whether expression would be increased by mimicking this natural spacing we converted pHGH107 to pHGH107-1 by opening the former with
Eco RI, digesting the resulting single strand ends with S1 endonuclease, and recircularizing by blunt-end ligation with T4 ligase. Although the resulting plasmid proved likewise capable of expressing HGH, it surprisingly did so to a lesser extent than did pGH107, as shown by direct radioimmunoassay.

It will be apparent to those skilled in the art that the present invention is not limited to the preferred embodiment just discussed, but rather only to the lawful scope of the appended claims. Variations other than those hitherto discussed will be apparent, whether in the choice of promoter system, parental plasmid, intended polypeptide product or elsewhere. For example, other promoter systems applicable to the present invention include the lambda promoter, the arabinose operon (phi 80 d ara) or the colicine E1, galactose, alkaline phosphatase or tryptophan promoter systems. Host organisms for bacterial expression may be chosen, e.g., from among the Enterobacteriaceae, such as strains of Escherichia coli and Salmonella; Bacillaceae, such as bacillus subtilis; Pneumococcus; Streptococcus; and Haemophilus influenzae. Of course, the choice of organism will control the levels of physical containment in cloning and expression that should be practiced to comply with National Institutes of Health Guidelines for Recombinant DNA, 43 Fed. Reg. 60,080 (1978).

While preferred for bench-scale practice of the present invention, E. Coli. x1776 could prove of limited practicality in large-scale industrial manufacture owing to the debilitations purposefully incorporated in it for biosafety reasons. With appropriate levels of physical, rather than biological, containment such organisms as E. Coli. K-12 strain 294, supra, and E. Coli. strain RR1, genotype: Pro-Leu-Thi-RB-recA+StrF Lac y- could be employed in larger scale operation. E. Coli. RR1 is derived from E. Coli HB101 (H.W. Boyer, et al, J. Mol.Bio. (1969) 41 459-472) by mating with E.
Coli K12 strain KL16 as the Hfr donor. See J.H. Miller, Experiments in Molecular Genetics (Cold Spring Harbor, New York, 1972). A culture of E. coli RRL was deposited October 30, 1978 with the American Type Culture Collection, without restriction as to access (ATCC No. 31343). A culture of x1776 was similarly deposited July 3, 1979 in the American Type Culture Collection (ATCC No. 31537). Deposits of the following were made in the American Type Culture Collection July 3, 1979: plasmid pGH107 (ATCC No. 40011); plasmid pGH6 (ATCC No. 40012); strain x1776 transformed with pGH 107 (ATCC No. 31538) and E. Coli K12 strain 294 transformed with pGH6 (ATCC No. 31539).

Organisms produced according to the invention may be employed in industrial scale fermentative production of human growth hormone, yielding product in quantities and for applications hitherto unattainable. For example, transformant E. coli cultures may be grown up in aqueous media in a steel or other fermentation vessel conventionally aerated and agitated, in aqueous media at, e.g., about 37°C and near neutral pH (e.g., pH 7 ± 0.3) supplied with appropriate nutrients such as carbohydrate or glycerol, nitrogen sources such as ammonia sulfate, potassium sources such as potassium phosphate, trace elements, magnesium sulfate and the like. Transformant organisms preferably exhibit one or more selection characteristics, such as antibiotic resistance, so that selection pressures may be imposed to discourage competitive growth of wild-type E. Coli. As an example, in the case of an ampicillin or tetracycline-resistant organism the antibiotic may be added to the fermentation medium to select out wild-type organisms which lack the resistance characteristic.

Upon completion of fermentation the bacterial suspension is centrifuged or the cellular solids otherwise collected from the broth and then lysed by physical or chemical means. Cellular debris is removed from
supernatant and soluble growth hormone isolated and purified.

Human growth hormone may be purified from bacterial extracts using one or a combination of (1) polyethyleneimine fractionation; (2) gel filtration chromatography on Sephacryl S-200; (3) ion exchange chromatography on Bioex-70 resin or CM Sephadex; (4) ammonium sulphate and/or pH fractionation; and (5) affinity chromatography using antibody resins prepared from anti-HGH IgG isolated from immunosensitized animals or hybridomas; and desorbed under acid or slightly denaturing conditions.
Claims:

1. In the method of constructing a replicable cloning vehicle capable, in a microbial organism, of expressing a particular polypeptide of known amino acid sequence wherein a gene coding for the polypeptide is inserted into a cloning vehicle and placed under the control of an expression promoter, the improvement which comprises:

   a) obtaining by reverse transcription from messenger RNA a first gene fragment for an expression product other than said polypeptide, which fragment comprises at least a substantial portion of the coding sequence for said polypeptide;

   b) where the first fragment comprises protein-encoding codons for amino acid sequences other than those contained in said polypeptide, eliminating the same while retaining at least a substantial portion of said coding sequence, the resulting fragment nevertheless coding for an expression product other than said polypeptide;

   c) the product of step (a) or, where required, step (b) being a fragment encoding less than all of the amino acid sequence of said polypeptide;

   d) providing by organic synthesis one or more gene fragments encoding the remainder of the amino acid sequence of said polypeptide, at least one of said fragments coding for the amino-terminal portion of the polypeptide; and

   d) deploying the synthetic gene fragment(s) of step (c) and that produced in step (a) or (b), as the case may be, in a
replicable cloning vehicle in proper reading phase relative to one another and under the control of an expression promoter; whereby a replicable cloning vehicle capable of expressing the amino acid sequence of said polypeptide is formed.

2. The method of claim 1 wherein the cloning vehicle of step (d) is a bacterial plasmid.

3. The method of claim 2 wherein the synthetic fragment encoding the amino-terminal portion of the polypeptide additionally codes for expression of a specifically cleavable amino acid sequence, and wherein the fragments are deployed downstream from and in reading phase with expressed protein-encoding codons, whereby the conjugated plasmid expression product may be specifically cleaved to yield the polypeptide.

4. The method of claim 2 wherein the amino acid sequence of the polypeptide is expressable unaccompanied by extraneous protein.

5. The method of claim 4 wherein the fragment of step (a) comprises at least a majority of the coding sequence for said polypeptide.

6. The method of claim 2 wherein a synthetic fragment and an mRNA transcript fragment are ligated to one another before their deployment in the cloning vehicle, and wherein the opposite ends of the fragment and of the transcript are variously single stranded or blunt so as to ensure ligation of the two fragments in the proper order for expression of said polypeptide.

7. The method of claim 5 wherein the polypeptide is human growth hormone, and wherein the first fragment
-25-
comprises protein-encoding codons for amino acid sequences other than those in human growth hormone, and wherein elimination step (b) yields the Hae III restriction enzyme fragment of the first fragment.

8. The method of claim 7 wherein step (b) includes digestion of the Hae III fragment with a different restriction enzyme, cleaving away codons for untranslated messenger RNA and simultaneously providing a single-stranded terminus at one end of the resulting fragment.

9. The method of claim 8 wherein the second restriction enzyme is Xma I.

10. A replicable bacterial plasmid capable, in a transformant bacterium, of expressing human growth hormone unaccompanied by extraneous conjugated protein.

11. A plasmid according to claim 10 whose human growth hormone-encoding gene comprises in substantial proportion cDNA or a replication thereof.

12. A plasmid according to claim 11 which exhibits resistance to at least one antibiotic.

13. A plasmid according to claim 12 which lacks the tet promoter yet exhibits tetracycline resistance.

14. A plasmid according to claim 13 in which the human growth hormone-encoding gene is under the control of tandem lac promoters.

15. The plasmid pHGH107.

16. The plasmid pHGH107-1.
17. A viable culture of bacterial transformants comprising plasmids according to claim 10.

18. A method of producing human growth hormone which comprises:
   (a) Disposing a culture according to claim 17 within a fermenter vessel comprising aeration and agitation means in an aqueous, nutriment-containing fermentation broth;
   (b) Growing up the culture under aeration and agitation while supplying additional nutriments as required to maintain vigorous growth.
   (c) separating the resulting cellular mass from the fermentation broth;
   (d) lysing the cells to free the contents thereof;
   (e) separating cellular debris from supernatant; and
   (f) isolating and purifying human growth hormone contained in the supernatant.

19. The method of claim 18 wherein the bacteria are transformant E. Coli. having a selection characteristic and wherein selection pressure is applied to discourage competition by wild-type E. Coli.

20. An expression plasmid comprising functional genes for ampicillin and tetracycline resistance and, lying between said genes, a tandem lac promoter system oriented to promote expression in the direction of the gene for tetracycline resistance, plural restriction sites being positioned downstream from said promoter system which yield, respectively, cohesive and blunt ends upon cleavage, permitting proper insertion of heterologous DNA between said sites so as to come under the control of said promoter system.

22. A plasmid according to claim 10 capable, in transformant E. Coli bacteria, of expressing the amino acid sequence successively depicted in Figures 1 and 3.

23. The method of claim 4 wherein the amino acid sequence of the polypeptide is expressed.
HGH (1-24)

Fig. 1.
 Ala Phe Asp Thr Tyr Gin Glu Phe Glu Glu Ala Tyr Ile Pro Lys Gin Gin Lys Tyr Ser Phe Leu Gin Asn Pro Gin Thr Ser
5'...G GCC UUU GAC ACC UAC CAG GAG UUU GAA GAA GCC UAU AUC CCA AAG GAA CAG UAU UCA UUC CUG CAG AAC CCC CAG ACC ACC UCC

Pst I

Leu Cys Phe Ser Gin Ser Ile Pro Thr Pro Ser Asn Arg Glu Thr Gin Gin Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser Leu Leu
CUC UGU UUC UCA GAG UCU AUU CCG ACA CCC UCC AAC AGG GAG GAA ACA CAA CAG AAA UCC AAC CUA GAG CUG CUC GCC AUC UCC CUG CUG

Leu Ile Gin Ser Trp Leu Gin Pro Val Gin Phe Leu Arg Ser Val Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser Asn Val Tyr
CUC AUC CAG UCG UGG CUG GAG CCC UUC CAG UCC AGG AGU GCC UUC CAC GCC AAC GCU CUA GUG UAC GCC GCC UCU GAC AGC AAC GUC UAU

Asp Leu Leu Lys Asp Leu Glu Gly Ile Gin Thr Leu Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly Gin Ile Phe Lys Gin
GAC CUC CUA AAG GAC CUA GAG GAA GCC UAC CAA ACG CUG AUG GGG AGG CUG GAA GAA GCC AGC CCC CGG AGU GGG CAG AUC UUC AAG CAG

Sgl II

Thr Tyr Ser Lys Phe Asp Thr Asn Ser His Asn Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys Asp Met Asp
ACC UAC AGC AAG UUC GAC ACA AAG UCA CAC AAC GAU GAC GCA CUA CUC AAC AAG AAC UAC GGG CUG CUC UAG UCC UGC AUG GAC

180

Lys Val Glu Thr Phe Leu Arg Ile Val Gin Cys Arg Ser Val Glu Gly Ser Cys Gly Phe Stop
AAG GUC GAG ACA UUC CUG CCC AUC GUG CAG UGC UCU GUG GAG GGC AGG UCU GCC UGG GCC AGG UGG GCG UGG GCA GCC GCC GCC GCC GCC GCC

Pvu II

Sma I

Xma I

GCCUCGCCGCCGCC...3'

Hae III

**FIG. 3.**
**Fig. 4.**

Diagram showing the process of cloning a human pituitary mRNA into a plasmid (pBR322). The mRNA is reverse transcribed using reverse transcriptase and Klenow Pol I to generate double-stranded cDNA (d.s. cDNA). The cDNA is then purified and fragment enriched using a specific restriction enzyme (Hae III). Terminal transferase is used to add terminal nucleotides, and the cDNA is then annealed and transformed into yeast (Y1776) to create the plasmid pHGH31.
Fig. 5.
# INTERNATIONAL SEARCH REPORT

**International Application No:** PCT/US80/00838

## I. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both National Classification and IPC:

- **INT. CL.** C12N 15/00; 1/00; C12P 21/00; 21/02; 21/04
- **U.S. CL.** 435/172, 317, 68, 70, 71, 253

## II. FIELDS SEARCHED

<table>
<thead>
<tr>
<th>Classification System</th>
<th>Classification Symbols</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>435/172, 317, 68, 70, 71, 253</td>
</tr>
</tbody>
</table>

*Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched.*

## III. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to Claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A,E</td>
<td>US,A, 4,237,224, PUBLISHED 02 DECEMBER 1980, COHEN ET AL.</td>
<td>1-23</td>
</tr>
<tr>
<td>A,P</td>
<td>US,A, 4,190,495, PUBLISHED 26 FEBRUARY 1980, CURTISS, III.</td>
<td>1-23</td>
</tr>
<tr>
<td>A</td>
<td>N, PROC. NAT'L. ACAD. SCI., USA 75, 3727-3731 (1978).</td>
<td>1-23</td>
</tr>
<tr>
<td>A</td>
<td>N, SCIENCE 196, 1313-1319 (1977).</td>
<td>1-23</td>
</tr>
<tr>
<td>A</td>
<td>N, GENE 2, 95-113 (1977).</td>
<td>1-23</td>
</tr>
<tr>
<td>A</td>
<td>N, NATURE 275, 617-624(1978).</td>
<td>1-23</td>
</tr>
<tr>
<td>A</td>
<td>N, PROC. NAT'L ACAD. SCI., USA 73, 3900-3904, (1978).</td>
<td>1-23</td>
</tr>
<tr>
<td>A</td>
<td>N, PROC. NAT'L ACAD. SCI., USA 75, 5765-5769 (1978).</td>
<td>1-23</td>
</tr>
</tbody>
</table>

*Special categories of cited documents:

**A** document defining the general state of the art

**E** earlier document but published on or after the international filing date

**L** document cited for special reason other than those referred to in the other categories

**O** document referring to an oral disclosure, use, exhibition or other means

**P** document published prior to the international filing date but on or after the priority date claimed

**T** later document published on or after the international filing date or priority date and not in conflict with the application, but cited to understand the principle or theory underlying the invention

**X** document of particular relevance

## IV. CERTIFICATION

- **Date of the Actual Completion of the International Search:** 08 DECEMBER 1980
- **Date of Mailing of this International Search Report:** 09 DEC 1980
- **International Searching Authority:** ISA/US
- **Signature of Authorized Officer:** ALVIN E. TANENHOLTZ
### FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

| A | N, PROC. NAT'L. ACAD. SCI.; USA 76, 106-110, 1979. | 1-23 |
| A | N, SCIENCE 205, 602-606(1979). | 1-23 |
| A | N, NATURE 281, 544-548 (1979). | 1-23 |

### V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers __________, because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim numbers __________, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

### VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

I. Claims 1-9 drawn to a method of making a cloning vehicle.
II. Claims 10-16, 20, & 21 to cloning vehicles.
III. Claim 17 for bacterial culture
IV. Claims 18 & 19 for method of producing human growth hormone.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the International application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

Remark on Protest
- The additional search fees were accompanied by applicant's protest.
- No protest accompanied the payment of additional search fees.